Circ_0005615 contributes to the progression and Bortezomib resistance of multiple myeloma by sponging miR-185-5p and upregulating IRF4
- PMID: 36136989
- DOI: 10.1097/CAD.0000000000001378
Circ_0005615 contributes to the progression and Bortezomib resistance of multiple myeloma by sponging miR-185-5p and upregulating IRF4
Abstract
Circular RNAs (circRNAs) have been shown to play critical regulatory roles in multiple myeloma progression. Here, we aimed to explore the biologic role of circ_0005615 in multiple myeloma progression and its associated mechanism. Cell counting kit-8 assay was conducted to analyze the bortezomib resistance and proliferation of multiple myeloma cells. Cell proliferation was also analyzed by 5-Ethynyl-2'-deoxyuridine incorporation and flow cytometry assays. Cell apoptosis was assessed by flow cytometry. The interaction between microRNA-185-5p (miR-185-5p) and circ_0005615 or interferon regulatory factor 4 (IRF4) was verified by the dual-luciferase reporter and RNA immunoprecipitation (RIP) assays. A xenograft tumor model was established in non-obese diabetic/server combined immune-deficiency mice to analyze the roles of circ_0005615 in tumor growth and bortezomib resistance. Circ_0005615 was upregulated in multiple myeloma tissues and cell lines. Circ_0005615 knockdown restrained the bortezomib resistance and proliferation and induced the apoptosis of multiple myeloma cells. Circ_0005615 acted as a molecular sponge for miR-185-5p, and the antitumor effects mediated by circ_0005615 knockdown were reversed by silencing miR-185-5p. IRF4 was confirmed as a direct target of miR-185-5p, and miR-185-5p overexpression-induced antitumor influences could be counteracted by IRF4 overexpression. Circ_0005615 could positively regulate IRF4 expression by sponging miR-185-5p in multiple myeloma cells. Circ_0005615 knockdown suppressed the growth and bortezomib resistance of xenograft tumors in vivo. Circ_0005615 contributed to the malignant progression and bortezomib resistance of multiple myeloma through mediating miR-185-5p/IRF4 signaling.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p/JAG1 axis.Cell Cycle. 2020 Dec;19(23):3289-3302. doi: 10.1080/15384101.2020.1839701. Epub 2020 Nov 1. Cell Cycle. 2020. PMID: 33131409 Free PMC article.
-
Novel insights into the circ_0003489/let-7b-5p/GLUT1 axis and its possible role in multiple myeloma.Transpl Immunol. 2025 Feb;88:102165. doi: 10.1016/j.trim.2024.102165. Epub 2024 Dec 21. Transpl Immunol. 2025. PMID: 39716648
-
Circ_0005875 sponges miR-502-5p to promote renal cell carcinoma progression through upregulating E26 transformation specific-1.Anticancer Drugs. 2022 Jan 1;33(1):e286-e298. doi: 10.1097/CAD.0000000000001205. Anticancer Drugs. 2022. PMID: 34407050
-
IRF4: Immunity. Malignancy! Therapy?Clin Cancer Res. 2009 May 1;15(9):2954-61. doi: 10.1158/1078-0432.CCR-08-1845. Epub 2009 Apr 21. Clin Cancer Res. 2009. PMID: 19383829 Free PMC article. Review.
-
Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies.Pharmaceuticals (Basel). 2023 Jan 12;16(1):111. doi: 10.3390/ph16010111. Pharmaceuticals (Basel). 2023. PMID: 36678608 Free PMC article. Review.
Cited by
-
Epigenetic Alterations as Vital Aspects of Bortezomib Molecular Action.Cancers (Basel). 2023 Dec 23;16(1):84. doi: 10.3390/cancers16010084. Cancers (Basel). 2023. PMID: 38201512 Free PMC article. Review.
-
Recent Progress of CircRNAs in Hematological Malignancies.Int J Med Sci. 2024 Sep 30;21(13):2544-2561. doi: 10.7150/ijms.98156. eCollection 2024. Int J Med Sci. 2024. PMID: 39439468 Free PMC article. Review.
-
Knockdown of circ_0005615 enhances the radiosensitivity of colorectal cancer by regulating the miR-665/NOTCH1 axis.Open Med (Wars). 2023 May 9;18(1):20230678. doi: 10.1515/med-2023-0678. eCollection 2023. Open Med (Wars). 2023. PMID: 37727322 Free PMC article.
References
-
- Cullis J. Haematology: multiple myeloma. Clin Med (Lond) 2019; 19:188.
-
- Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016; 91:719–734.
-
- Ritchie DS, Quach H, Fielding K, Neeson P. Drug-mediated and cellular immunotherapy in multiple myeloma. Immunotherapy 2010; 2:243–255.
-
- Chen LL, Yang L. Regulation of circRNA biogenesis. RNA Biol 2015; 12:381–388.
-
- Panda AC. Circular RNAs Act as miRNA Sponges. Adv Exp Med Biol 2018; 1087:67–79.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous